French multinational healthcare company Sanofi announced on Tuesday that new research that is to be presented at the 2022 American Society of Clinical Oncology (ASCO) Annual Meeting from June 3-7 underscores the company's commitment to improving care across its core focus areas, including multiple myeloma, lung and breast cancers.

Dietmar Berger chief medical officer, global head of Development at Sanofi, said, 'Oncology is a core area for Sanofi, as evidenced by the doubling of our pipeline between 2019 and 2022. As we continue to pursue transformative research to develop advanced medicines for people living with cancer, our portfolio has grown to more than ten therapies in clinical trials. In parallel, we continue to leverage external innovation through strategic collaborations and investments in cutting edge technologies. Over ten value-creating acquisitions and business development deals in the past two years have reshaped our footprint in oncology, expanding our capacities with leading talent, as well as state-of-the-art molecules and technologies in immuno-oncology, molecular oncology, and genomic medicine.'